A novel approach for next‐generation sequencing of circulating tumor cells

Stephanie S. Yee(University of Kentucky), Erica L. Carpenter(University of Pennsylvania), Angela DeMichele(University of Pennsylvania), Lewis A. Chodosh(University of Pennsylvania), Bijal Kakrecha(University of Pennsylvania), Robert Daber(University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania), JulieAnn Rader(Children's Hospital of Philadelphia), Daniel DeSloover(Hospital of the University of Pennsylvania), Tatiana Blanchard(University of Pennsylvania), George K. Belka(Translational Therapeutics (United States)), Shrey Sukhadia(Dartmouth–Hitchcock Medical Center), Alan J. Fox(Hospital of the University of Pennsylvania), Andrea B. Troxel(Andover Eye Associates), David Lieberman(University of Pennsylvania), Jianhua Zhao(Southwest Petroleum University)
Molecular Genetics & Genomic Medicine
February 28, 2016
10.1002/mgg3.210
Cited by 21

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563